Gerty Schreibelt

7.2k citations

77 papers · 5.3k indexed · h-index 39

Immunology top 0.5%
- Immunotherapy and Immune Responses 56
- T-cell and B-cell Immunology 23
- Immune Cell Function and Interaction 14
- Immune Response and Inflammation 6
Oncology top 1%
- Cancer Immunotherapy and Biomarkers 25
- CAR-T cell therapy research 15
Neurology top 1%
Biological Psychiatry top 5%
Pathology and Forensic Medicine top 2%
- Genetic factors in colorectal cancer 6
Molecular Biology
- vaccines and immunoinformatics approaches 12

Co-authors: I. Jolanda M. de Vries Carl G. Figdor Helga E. de Vries Jack van Horssen Kalijn F. Bol Gosse J. Adema Jurjen Tel Cornelis J.A. Punt
Cited by: Immunology Oncology Neurology
Journals: Journal of Clinical Investigation (1 paper)Nature Communications (1 paper)Journal of Clinical Oncology (1 paper)
Partner nations: Netherlands United States Germany

In The Last Decade

Gerty Schreibelt

76 papers receiving 5.2k citations

Peers

Countries citing papers authored by Gerty Schreibelt

Since Specialization

Citations

This map shows the geographic impact of Gerty Schreibelt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gerty Schreibelt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gerty Schreibelt more than expected).

Fields of papers citing papers by Gerty Schreibelt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gerty Schreibelt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gerty Schreibelt. The network helps show where Gerty Schreibelt may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Gerty Schreibelt, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Gerty Schreibelt Line = papers co-authored together Gerty Schreibelt links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Unraveling mutagenic processes influencing the tumor mutational patterns of individuals with constitutional mismatch repair deficiency Nature Communications ·Dilys Weijers,Snežana Hinić,Emma Kroeze,Mark A.J. Gorris,Gerty Schreibelt,Sjors Middelkamp,Arjen R. Mensenkamp,Reno S. Bladergroen,Kiek Verrijp,Nicoline Hoogerbrugge,Pieter Wesseling,Rachel S. van der Post,Jan Loeffen,Corrie Gidding,Mariëtte Ca van Kouwen,I. Jolanda M. de Vries,Ruben van Boxtel,Richarda M. de Voer,Marjolijn C.J. Jongmans,Roland P. Kuiper	2025	2
2	Design of TOLERANT: phase I/II safety assessment of intranodal administration of HSP70/mB29a self-peptide antigen-loaded autologous tolerogenic dendritic cells in patients with rheumatoid arthritis BMJ Open ·Arie Jan Stoppelenburg,Gerty Schreibelt,Bouke Koeneman,Paco M J Welsing,Evert-Jan Breman,Laureen Lammers,Anna de Goede,Tjitske Duiveman‐de Boer,Willem van Eden,Paul Leufkens,I. Jolanda M. de Vries,Femke Broere,Jacob M. van Laar	2024	4
3	Challenges of Neoantigen Targeting in Lynch Syndrome and Constitutional Mismatch Repair Deficiency Syndrome Cancers ·Asima Abidi,Mark A.J. Gorris,Evan Brennan,Marjolijn C.J. Jongmans,Dilys Weijers,Roland P. Kuiper,Richarda M. de Voer,Nicoline Hoogerbrugge,Gerty Schreibelt,I. Jolanda M. de Vries	2021	5
4	Immunological responses to adjuvant vaccination with combined CD1c ⁺ myeloid and plasmacytoid dendritic cells in stage III melanoma patients OncoImmunology ·Martine Bloemendal,Kalijn F. Bol,Steve Boudewijns,Mark A.J. Gorris,Johannes H.W. de Wilt,Sandra Croockewit,Michelle M. van Rossum,Anna L. de Goede,Katja Petry,Rutger H.T. Koornstra,Carl G. Figdor,Winald R. Gerritsen,Gerty Schreibelt,I. Jolanda M. de Vries	2021	22
5	Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy Clinical & Translational Oncology ·Martine Bloemendal,Mark J.A. Rietveld,Wouter W. van Willigen,Winald R. Gerritsen,Carl G. Figdor,Han J. Bonenkamp,Harm Westdorp,Steve Boudewijns,Rutger H.T. Koornstra,Eddy Adang,Gerty Schreibelt,Petronella B. Ottevanger,I. Jolanda M. de Vries,Kalijn F. Bol	2018	6
6	Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome Cancer Letters ·Harm Westdorp,Sigrid Kolders,Nicoline Hoogerbrugge,I. Jolanda M. de Vries,Marjolijn C.J. Jongmans,Gerty Schreibelt	2017	43
7	Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines Cancer Research ·Ghaith Bakdash,Sonja I. Buschow,Mark A.J. Gorris,Altuna Halilović,Stanleyson V. Hato,Annette E. Sköld,Gerty Schreibelt,Simone P. Sittig,Ruurd Torensma,Tjitske Duiveman‐de Boer,Christoph Schröder,Evelien Smits,Carl G. Figdor,I. Jolanda M. de Vries	2016	90
8	Proteomics of Human Dendritic Cell Subsets Reveals Subset-Specific Surface Markers and Differential Inflammasome Function Cell Reports ·Kuntal Worah,Till S. M. Mathan,Thien‐Phong Vu Manh,Shivakumar Keerthikumar,Gerty Schreibelt,Jurjen Tel,Tjitske Duiveman‐de Boer,Annette E. Sköld,Annemiek B. van Spriel,I. Jolanda M. de Vries,Martijn A. Huynen,Hans J. C. T. Wessels,Jolein Gloerich,Marc Dalod,Edwin Lasonder,Carl G. Figdor,Sonja I. Buschow	2016	55
9	Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy Expert Review of Clinical Immunology ·Ghaith Bakdash,Inge Schreurs,Gerty Schreibelt,Jurjen Tel	2014	22
10	Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy OncoImmunology ·Florian Wimmers,Erik H.J.G. Aarntzen,Gerty Schreibelt,Joannes F.M. Jacobs,Cornelis J.A. Punt,Carl G. Figdor,I. Jolanda M. de Vries	2014	3
11	Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients Cancer Research ·Jurjen Tel,Erik H.J.G. Aarntzen,Tetsuro Baba,Gerty Schreibelt,Barbara M. Schulte,Daniel Benítez‐Ribas,Otto C. Boerman,Sandra Croockewit,Wim J.G. Oyen,Michelle van Rossum,Gregor Winkels,Pierre G. Coulie,Cornelis J.A. Punt,Carl G. Figdor,I. Jolanda M. de Vries	2013	289
12	Targeting of 111In-Labeled Dendritic Cell Human Vaccines Improved by Reducing Number of Cells Clinical Cancer Research ·Erik H.J.G. Aarntzen,Mangala Srinivas,F. Bonetto,Luis J. Cruz,Pauline Verdijk,Gerty Schreibelt,Mandy van de Rakt,W. Joost Lesterhuis,Maichel van Riel,Cornelius J.A. Punt,Gosse J. Adema,Arend Heerschap,Carl G. Figdor,Wim J.G. Oyen,I. Jolanda M. de Vries	2013	49
13	Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based Vaccination Cancer Research ·Erik H.J.G. Aarntzen,I. Jolanda M. de Vries,W. Joost Lesterhuis,Danita H. Schuurhuis,Joannes F.M. Jacobs,Kalijn F. Bol,Gerty Schreibelt,Roel Mus,Johannes H.W. de Wilt,John B.A.G. Haanen,Dirk Schadendorf,Alexandra Croockewit,Willeke A.M. Blokx,Michelle M. van Rossum,William W. Kwok,Gosse J. Adema,Cornelis J.A. Punt,Carl G. Figdor	2012	131
14	Skin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell–Based Vaccination in Metastatic Melanoma Cancer Research ·Erik H.J.G. Aarntzen,Kalijn F. Bol,Gerty Schreibelt,Joannes F.M. Jacobs,W. Joost Lesterhuis,Michelle M. van Rossum,Gosse J. Adema,Carl G. Figdor,Cornelis J.A. Punt,I. Jolanda M. de Vries	2012	42
15	Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma Patients Clinical Cancer Research ·Erik H.J.G. Aarntzen,Gerty Schreibelt,Kalijn F. Bol,W. Joost Lesterhuis,Alexandra Croockewit,Johannes H.W. de Wilt,Michelle M. van Rossum,Willeke A.M. Blokx,Joannes F.M. Jacobs,Tjitske Duiveman‐de Boer,Danita H. Schuurhuis,Roel Mus,Kris Thielemans,I. Jolanda M. de Vries,Carl G. Figdor,Cornelis J.A. Punt,Gosse J. Adema	2012	80
16	Route of Administration Modulates the Induction of Dendritic Cell Vaccine–Induced Antigen-Specific T Cells in Advanced Melanoma Patients Clinical Cancer Research ·W. Joost Lesterhuis,I. Jolanda M. de Vries,Gerty Schreibelt,Annechien J.A. Lambeck,Erik H.J.G. Aarntzen,Joannes F.M. Jacobs,Nicole M. Scharenborg,Mandy W.M.M. van de Rakt,Annemiek J. de Boer,Sandra Croockewit,Michelle M. van Rossum,Roel Mus,Wim J.G. Oyen,Otto C. Boerman,Sophie Lucas,Gosse J. Adema,Cornelis J.A. Punt,Carl G. Figdor	2011	138
17	Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice Journal of Clinical Investigation ·W. Joost Lesterhuis,Cornelis J.A. Punt,Stanleyson V. Hato,Dagmar Eleveld-Trancikova,Bas Jansen,Stefan Nierkens,Gerty Schreibelt,Annemiek de Boer,Carla M.L. van Herpen,Johannes H.A.M. Kaanders,J. Han van Krieken,Gosse J. Adema,Carl G. Figdor,I. Jolanda M. de Vries	2011	275
18	Radical changes in multiple sclerosis pathogenesis Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Jack van Horssen,Maarten E. Witte,Gerty Schreibelt,Helga E. de Vries	2010	268
19	Maturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration Cancer Immunology Immunotherapy ·A.C.I. Boullart,Erik H.J.G. Aarntzen,Pauline Verdijk,Joannes F.M. Jacobs,Danita H. Schuurhuis,Daniel Benítez‐Ribas,Gerty Schreibelt,Mandy W.M.M. van de Rakt,Nicole M. Scharenborg,Annemiek de Boer,Matthijs Kramer,Carl G. Figdor,Cornelis J.A. Punt,Gosse J. Adema,I. Jolanda M. de Vries	2008	122
20	NAD(P)H:quinone oxidoreductase 1 expression in multiple sclerosis lesions Free Radical Biology and Medicine ·Jack van Horssen,Gerty Schreibelt,Lars Bø,Lisette Montagne,Benjamin Drukarch,F. L. Van Muiswinkel,Helga E. de Vries	2006	60

About Gerty Schreibelt

Gerty Schreibelt is a scholar working on Immunology, Oncology and Biological Psychiatry, having authored 77 papers that have together received 5.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (56 papers), Cancer Immunotherapy and Biomarkers (25 papers), T-cell and B-cell Immunology (23 papers), CAR-T cell therapy research (15 papers), Immune Cell Function and Interaction (14 papers), vaccines and immunoinformatics approaches (12 papers), Genetic factors in colorectal cancer (6 papers) and Immune Response and Inflammation (6 papers). The work is most often cited by research in Immunology (3.3k citations), Oncology (2.1k citations) and Neurology (581 citations). Gerty Schreibelt has collaborated with scholars based in Netherlands, United States and Germany. Frequent co-authors include I. Jolanda M. de Vries, Carl G. Figdor, Helga E. de Vries, Jack van Horssen, Kalijn F. Bol, Gosse J. Adema, Jurjen Tel, Cornelis J.A. Punt, Winald R. Gerritsen and Erik H.J.G. Aarntzen. Their work appears in journals such as Journal of Clinical Investigation, Nature Communications and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact